{
  "main_header": {
    "sid": 351394,
    "name": "Desh Rakshak",
    "stock_name": "Desh Rakshak",
    "full_name": "Desh Rakshak Aushdhalaya Ltd",
    "name_url": "stocks-analysis/desh-rakshak",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "25.75",
    "chg": -1,
    "chgp": "-3.74%",
    "dir": -1,
    "prev_price": "26.75",
    "mcapval": "15.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531521,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE971E01016",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "100 ",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/desh-rakshak-351394-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Desh Rakshak Aushdhalaya Ltd Downgraded to Strong Sell Amid Mixed Financial and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/desh-rakshak-aushdhalaya-ltd-downgraded-to-strong-sell-amid-mixed-financial-and-valuation-signals-3998427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DeshRakshakAush_mojoScore_3998427.png",
        "date": "2026-05-19 09:01:39",
        "description": "Desh Rakshak Aushdhalaya Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. Despite an improvement in valuation metrics, the company’s weak financial trends and poor quality indicators have weighed heavily on the overall assessment, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Desh Rakshak Aushdhalaya Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/desh-rakshak-aushdhalaya-ltd-valuation-shifts-signal-renewed-price-attractiveness-3997703",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/DeshRakshakAush_valuationdot_3997703.png",
        "date": "2026-05-19 08:00:38",
        "description": "Desh Rakshak Aushdhalaya Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, driven by changes in its price-to-earnings and price-to-book value ratios. Despite a challenging year-to-date performance and a micro-cap status, the company’s valuation now presents a compelling case for investors seeking opportunities in the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 15,
    "sid": "351394",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/desh-rakshak-aushdhalaya-351394"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Pre Intimation Of The Board Meeting As Per Regulation 29 Of The SEBI (Listing Obligations & Disclosure Requirements) Reg 2015 And Closure Of Trading Window",
      "datetime": "09-Aug-2026",
      "details": "Desh Rakshak Aushdhalaya Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve inter alia to take note consider and/or approve the following businesses:",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "14-Jul-2026",
      "details": "The Company enclosed Confirmation Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 issued by M/s. Nivis Corpserve LLP Registrar and Share Transfer Agent of the Company",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "Intimation for closure of trading window for all the designated persons designated employees specified persons connected persons insiders and their immediative relatives pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Desh Rakshak Aushdhalaya Ltd Downgraded to Strong Sell Amid Mixed Financial and Valuation Signals

2026-05-19 09:01:39

Desh Rakshak Aushdhalaya Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. Despite an improvement in valuation metrics, the company’s weak financial trends and poor quality indicators have weighed heavily on the overall assessment, prompting a reassessment of its investment appeal.

Read More

Desh Rakshak Aushdhalaya Ltd: Valuation Shifts Signal Renewed Price Attractiveness

2026-05-19 08:00:38

Desh Rakshak Aushdhalaya Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, driven by changes in its price-to-earnings and price-to-book value ratios. Despite a challenging year-to-date performance and a micro-cap status, the company’s valuation now presents a compelling case for investors seeking opportunities in the Pharmaceuticals & Biotechnology sector.

Read More

View All News